Search

Search Results

1. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

   Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides remain at increased risk for...

   Daniel Tobias Michaeli, Julia Caroline Michaeli, ... Thomas Michaeli in American Journal of Cardiovascular Drugs

   Article Open access 24 July 2023
   

2. Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study

   Gout attacks are treated with uric-lowering and anti-inflammatory drugs. In patients with gout, non-steroidal anti-inflammatory drugs (NSAIDs) could...

   Anne Bech-Drewes, Kasper Bonnesen, ... Morten Schmidt in Rheumatology International

   Article Open access 06 April 2024
   

3. A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes

   Uric acid has been linked to various disease outcomes. However, it remains unclear whether uric acid-lowering therapy could be repurposed as a...

   Lijuan Wang, Ines Mesa-Eguiagaray, ... Evropi Theodoratou in European Journal of Epidemiology

   Article Open access 11 July 2024
   

4. Characteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021

   Background

   Cardiovascular disease remains the leading cause of death worldwide and brings a heavy burden. However, the development of cardiovascular...

   Jun Hao, Chen Li, ... Wen Hui in American Journal of Cardiovascular Drugs

   Article 14 March 2023
   

5. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

   Antiangiogenics are associated with an increased risk of major adverse cardiac and cerebrovascular events (MACE). The identification of at-risk...

   Bernardo Stefanini, Francesco Tovoli, ... Fabio Piscaglia in Internal and Emergency Medicine

   Article Open access 29 March 2024
   

6. Repurposing drugs to treat cardiovascular disease in the era of precision medicine

   Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The...

   Mena Abdelsayed, Eric J. Kort, ... Mark Mercola in Nature Reviews Cardiology

   Article 23 May 2022
   

7. Predicting the effectiveness of drugs used for treating cardiovascular conditions in newborn infants

   Background

   Cardiovascular support (CVS) treatment failure (TF) is associated with a poor prognosis in preterm infants.

   Methods

   Medical charts of...

   María Carmen Bravo, Raquel Jiménez, ... Adelina Pellicer in Pediatric Research

   Article 13 December 2023
   

8. Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs

   Evidence suggests that chronic venous disease (CVD) may be a cardiovascular disorder, as patients with CVD are prone to developing arterial...

   Sergio Gianesini, Leonardo De Luca, ... Fedor Lurie in Advances in Therapy

   Article Open access 28 September 2023
   

9. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs

   Sexual health has a fundamental role in overall health and well-being, and a healthy and dynamic sex life can make an important contribution to a...

   Dimitrios Terentes-Printzios, Nikolaos Ioakeimidis, ... Charalambos Vlachopoulos in Nature Reviews Cardiology

   Article 30 July 2021
   

10. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases

    Purpose of Review

    RNA therapeutics are a new and rapidly expanding class of drugs to prevent or treat a wide spectrum of diseases. We discuss the...

    Nada Bejar, Trinh T. Tat, Daniel L. Kiss in Current Atherosclerosis Reports

    Article 02 April 2022
    

11. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study

    Objective

    This study examined the risk of cardiovascular disease (CVD) associated with the disease-modifying anti-rheumatic drugs (DMARDs) in...

    Yinan Huang, Sandeep K. Agarwal, ... Rajender R. Aparasu in Clinical Rheumatology

    Article 04 August 2023
    

12. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study

    Aims/hypothesis

    We aimed to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty...

    Arunkumar Krishnan, Carolin V. Schneider, ... Saleh A. Alqahtani in Diabetologia

    Article Open access 20 December 2023
    

13. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study

    Since pandemic start, patients may have faced difficulties in accessing to care and treatment. This study aimed at assessing the impact of COVID-19...

    Clément Mathieu, Elodie Pambrun, ... Antoine Pariente in European Journal of Epidemiology

    Article 21 September 2022
    

14. The need for new clinical trials of old cardiovascular drugs

    Christopher B. Granger, Stuart J. Pocock, Bernard J. Gersh in Nature Reviews Cardiology

    Article 16 December 2022

15. Cardiovascular Outcome Trials with Glucose-Lowering Drugs

    Purpose of Review

    This review summarizes recent cardiovascular outcome trials (CVOTs) with glucose-lowering drugs.

    Recent Findings

    The majority of...

    Tina K. Thethi, Anika Bilal, Richard E. Pratley in Current Cardiology Reports

    Article 03 June 2021
    

16. Update in uric acid, hypertension, and cardiovascular diseases

    A direct relationship between serum uric acid levels and hypertension, cardiovascular, renal and metabolic diseases has been reported in many basic...

    Masanari Kuwabara, Takahide Kodama, ... Miguel A. Lanaspa in Hypertension Research

    Article 18 April 2023
    

17. Cardiovascular effects of approved drugs for rheumatoid arthritis

    The risk of cardiovascular disease is increased in patients with rheumatoid arthritis compared with the general population owing to the influence of...

    Fabiola Atzeni, Javier Rodríguez-Carrio, ... Zoltán Szekanecz in Nature Reviews Rheumatology

    Article 08 April 2021
    

18. Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities

    Psoriasis is now considered a systemic disease, and several comorbidities have been described such as cardiovascular diseases, neurologic and...

    Luca Potestio, Nello Tommasino, ... Matteo Megna in Dermatology and Therapy

    Article Open access 09 April 2024

19. Reducing Cardiovascular Disease—An Alternative Approach

    Purpose

    Statin drugs are effective at reducing cardiovascular events, but adherence to statin therapy remains a problem for patients and their...

    Hetal Boricha, James C. Blankenship, David S. Schade in Cardiovascular Drugs and Therapy

    Article 08 July 2024
    

20. Drug therapy problems among hospitalized patients with cardiovascular disease

    Background

    Optimal utilization of cardiovascular drugs is crucial in reducing morbidity and mortality associated with cardiovascular diseases....

    Yirga Legesse Niriayo, Roba Kifle, ... Kidu Gidey in BMC Cardiovascular Disorders

    Article Open access 15 January 2024